Pipeline 2

Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and autoimmune diseases. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.

Program Cell Type
Functionality
Target(s) Indication(s) Research PreClin Phase 1 Phase 2 Phase 3
iPSC-derived Cell Products
FT516 iNK
hnCD16

CD20 BCL + CD20 mAb

 Hematology

n/a AML

FT596 iNK
hnCD16 + IL15RF + CAR-19
CD19, CD20 BCL, CLL ± CD20 mAb

FT538 iNK
hnCD16 + IL15RF + CD38-KO
n/a AML

 Solid Tumor

CD38 MM + CD38 mAb

EGFR/HER2/PD1/PD-L1 Solid Tumors + mAb

FT576 iNK
hnCD16 + IL15RF + CD38-KO + CAR-BCMA
BCMA, CD38 MM ± CD38 mAb

FT819 iT
CAR-19, TCR-KO
CD19 Hematology

FT536 iNK
hnCD16 + IL15RF + CD38-KO + CAR-MICA/B
MICA/B Solid tumors ± mAb

FT873 iT
hnCD16 + IL7RF + CAR-B7H3
B7H3 Solid tumors ± mAb

iPSC-derived Cell Products – Cancer Immunotherapy Collaborations
FT555/
Janssen
iNK
hnCD16 + IL15RF + CD38-KO + CAR-GPRC5D
GPRC5D, CD38 MM ± CD38 mAb

Janssen iNK,iT KLK2; undisclosed 3 tumor targets

FT825/Ono iNK,iT HER2; undisclosed 2 tumor targets

iPSC-DERIVED CELL PRODUCTS

Program Indication Phase
FT500
iNK
Non-engineered
Solid tumors + CPI 1
FT516
iNKhnCD16
AML 1
BCL + CD20 mAb 1
Solid tumors + PD-L1 mAb 1
FT596
iNK
hnCD16 + IL15RF + CAR-19
BCL, CLL ± CD20 mAb 1
FT538
iNK
hnCD16 + IL15RF + CD38-KO
AML 1
MM + CD38 mAb 1
Solid Tumors + mAb 1
FT576
iNK
hnCD16 + IL15RF + CD38-KO + CAR-BCMA
MM ± CD38 mAb 1
FT819
iT
CAR-19, TCR-KO
Hematology 1
FT536
iNK,iT
hnCD16 + IL15RF + CD38-KO + CAR-MICA/B
Solid tumors ± mAb 1
FT873
iNK,iT
hnCD16 + IL7RF + CAR-B7H3
Solid tumors ± mAb Pre

iPSC-DERIVED CELL PRODUCTS – CANCER IMMUNOTHERAPY COLLABORATIONS

Program Indication Phase
FT555/Janssen
iNK
hnCD16 + IL15RF + CD38-KO + CAR-GPRC5D
MM ± CD38 mAb Preclinical
Janssen
iNK/iT
3 tumor targets Preclinical
Ono Pharma
iNK/iT
2 tumor targets Preclinical

iPSC = induced pluripotent stem cell iNK = iPSC-derived NK Cell iT = iPSC-derived T cell mAb = monoclonal antibody CPI = checkpoint inhibitor hnCD16 = high affinity, non-cleavable CD16 Fc receptor IL15-RF = IL15 receptor fusion CD38-KO = CD38 knock-out CAR = chimeric antigen receptor TCR-KO = T-cell receptor knock-out AML = acute myelogenous leukemia BCL = B-cell lymphoma CLL = chronic lymphocytic leukemia  MM = Multiple myeloma

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

For more information about the data we collect please visit our Privacy Policy.